Muredach P. Reilly, MBBCH, MSCE
Assistant Professor of Medicine
Department: Medicine
Graduate Group Affiliations
Contact information
609 Biomedical Research Building II/III
421 Curie Blvd
University of Pennsylvania Medical Center
Philadelphia, PA 19104
421 Curie Blvd
University of Pennsylvania Medical Center
Philadelphia, PA 19104
Office: (215) 573-1214
Fax: (215) 573-2094
Fax: (215) 573-2094
Publications
Links
Search PubMed for articles
Institute for Translational Medicine and Therapeutics
Cardiovascular Division Faculty
Penn Health Profile
Search PubMed for articles
Institute for Translational Medicine and Therapeutics
Cardiovascular Division Faculty
Penn Health Profile
Education:
MBBCh (Medicine)
University College, Dublin, Ireland, 1988.
BS (Pharmacology)
University College Dublin, Ireland , 1990.
MSCE (Epidemiology and Biostatistics)
University of Pennsylvania, 2003.
Permanent linkMBBCh (Medicine)
University College, Dublin, Ireland, 1988.
BS (Pharmacology)
University College Dublin, Ireland , 1990.
MSCE (Epidemiology and Biostatistics)
University of Pennsylvania, 2003.
Description of CVI Expertise
CVI Program Unit(s):CVI Research Description:
Dr. Reilly has extensive training and expertise in cardiovascular medicine, preventive cardiology, clinical pharmacology, epidemiology and translational research.
His interests include (1) mechanisms of atherosclerosis in metabolic syndrome, diabetes and obesity, (2) the role on innate immunity in promoting atherosclerotic risk in metabolic syndrome, (3) the functions of adipose tissue in regulation of HDL cholesterol and reverse cholesterol transport, (4) genetics of atherosclerosis and dyslipidemia in high risk populations including type 2 diabetes, subjects with family history of CAD, populations with chronic kidney disease and in HIV infected populations, and (5) non-invasive imaging of atherosclerosis in humans.
Dr. Reilly employs a translational approach to his research including cell and animal based mechanistic studies, mechanistic patient-oriented, General Clinical Research Center studies as well as larger scale epidemiological studies in humans.
Selected Publications
Wolfe ML, Iqbal N, Gefter W, Mohler ER III, Rader DJ, Reilly MP.: Coronary artery calcification at electron beam CT is increased in asymptomatic type 2 diabetics independent of traditional risk factors. Journal of Cardiovascular Risk 9(6): 369-76, Dec 2002.Kawashiri M, Zhang Y, Usher D, Reilly M, Pure E, Rader DJ.: Effects of coexpression of LDLR and apolipoprotein E on cholesterol metabolism and atherosclerosis in LDLR-deficient mice. Journal of Lipid Research 42: 943-50, 2001.
Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA.: Cyclooxygenase inhibitors and the anti-platelet effect of aspirin. New England Journal of Medicine 345: 1809-17, Dec 2001.
Reilly MP, Mohler ER. : Cilostazol: Pharmacology and clinical utility. Annals of Pharmacotherapy 35: 48-56, 2001.
Reilly MP.: Seizures associated with hypoxic-ischemic cardiopulmonary disorders. In: Seizures, Medical Causes and Management. Delanty N. Page: 233-250, 2001.
Reilly MP, Rader DJ.: Clinical decision-making in the management of lipid disorders. Disease Management and Clinical Outcome 3: 30-37, 2001.
| Protocol | Title | Status |
|---|---|---|
| 804727 | A Pilot Study of Metabolic Effects of Low-Dose Endotoxemia(Clinical Protocol,Version date: July 17, 2006) | Recruiting |
| 706771 | Inflammation and the Metabolic Syndrome in Humans (Version 6.2, dated 12/21/2006) | Recruiting |
| 703615 | Penn Diabetes Heart Study (Protocol Amendment, version date 01/25/08) | Recruiting |
| 805670 | The Genetics of Evoked-Responses to Niacin and Endotoxemia: The GENE Study (Revised Protocol, version 29-May-2009) | Recruiting |
| 804384 | Genetics of Atherosclerosis in Renal Disease | Recruiting |
» Top